PR1 leukemia peptide vaccine

DB15276InvestigationalProtein Based Therapies

PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).

Mechanism: Pharmacologically active on Myeloblastin and HLA class I histocompatibility antigen, A alpha chain
Curator reviewed
Also known as: L-VALINE, L-VALYL-L-LEUCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-ASPARAGINYL-L-VALYL-L-THREONYL- · Nine amino acid polypeptide derived from proteinase 3 · PR-1 · PR1 · PR1 VAC

Resolves to

Compound

UNII54XUF2TZ7GCAS182253-77-6

Targets

P24158PRTN3P04439HLA-A

What you can answer from here — as of September 25, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with PR1 leukemia peptide vaccine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account